Bio

Alexandre-Raphael Wery is a Doctor in medicine from Brussels, Belgium. He specialized in clinical haematology at the Jules Bordet Institute (Université Libre de Bruxelles) and holds a special interest in acute myeloid leukaemia (AML) and cellular therapies such as allogeneic stem cell transplantation.

He received the Henri Tagnon research grant from the Académie Royale de Médecine de Belgique and is currently conducting his research at the Zhang lab (Professor Tian Yi Zhang) to improve disease monitoring in AML, using personalized circulating tumor DNA (ctDNA) profiling (CAPP-Seq technology), a blood-based approach designed to more sensitively track measurable residual disease (MRD), assess treatment response, refine risk stratification, and detect relapse earlier across AML and the myeloid disease spectrum.

Stanford Advisors

Contact

Additional Info

Links

Current Research and Scholarly Interests

AML. Measurable residual disease. Circulating tumor DNA. CAPP-Seq.

All Publications

  • Rare and complex three-way t(8;11;21) translocation in core-binding factor acute myeloid leukemia transforming into refractory mediastinal myeloid sarcoma: cytogenetic and molecular insights CANCER GENETICS Wery, A., Dalborgo, M., Heimann, P., Sidon, P., Dewispelaere, L., Poutakidou, D., Wittnebel, S., Lewalle, P., Farhat, H. 2026; 306: 17-20

    Abstract

    Core-binding factor (CBF) acute myeloid leukemia (AML) with t(8;21)(q22;q22)/RUNX1::RUNX1T1 is typically considered as a favorable-risk AML in the context of cytarabine-based intensive chemotherapy. However, in some situations such as additional adverse-risk mutations or cytogenetics, the prognosis and disease course may be more uncertain. Here, we report the case of a young patient diagnosed with CBF-AML and RUNX1::RUNX1T1 fusion gene, carrying a rare and complex three-way t(8;11;21)(q22;q13;q22) translocation, with mutated KIT, ASXL1 and TET2 genes, transforming into an aggressive and multi-refractory mediastinal myeloid sarcoma. This case illustrates that this scarcely reported variant might negatively impact the favorable prognosis of CBF-AML.

    View details for DOI 10.1016/j.cancergen.2026.05.007

    View details for Web of Science ID 001785034200001

    View details for PubMedID 42208169

https://orcid.org/0000-0002-8701-2068